Trials / Conditions / Adult T-cell Leukemia/Lymphoma

Adult T-cell Leukemia/Lymphoma

23 registered clinical trials studyying Adult T-cell Leukemia/Lymphoma — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma NCT07388563	National Cancer Institute (NCI)	Phase 1
Recruiting	Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma NCT07356245	Jonathan Brammer	Phase 2
Recruiting	Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like NCT07159620	The First Affiliated Hospital of Soochow University	Phase 2
Withdrawn	Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory L NCT05321940	Juan C. Ramos, MD	Phase 1
Recruiting	A Registry for People With T-cell Lymphoma NCT05978141	Memorial Sloan Kettering Cancer Center	—
Withdrawn	Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma NCT04639843	National Cancer Institute (NCI)	Phase 1
Recruiting	Two Step Haplo With Radiation Conditioning NCT05031897	Thomas Jefferson University	Phase 2
Suspended	Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("E NCT04301076	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refracto NCT04703192	Daiichi Sankyo	Phase 2
Completed	Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma NCT04102150	Daiichi Sankyo Co., Ltd.	Phase 2
Active Not Recruiting	BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma NCT03264131	UNC Lineberger Comprehensive Cancer Center	Phase 2
Active Not Recruiting	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lym NCT03113500	City of Hope Medical Center	Phase 2
Completed	Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma NCT02631746	National Cancer Institute (NCI)	Phase 2
Completed	Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma NCT02737046	University of Miami	Phase 2
Completed	A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymp NCT02588651	Deepa Jagadeesh	Phase 2
Completed	Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma NCT02652715	Mayo Clinic	N/A
Completed	A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma NCT01724177	Celgene	Phase 2
Completed	KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) NCT01626664	Kyowa Kirin, Inc.	Phase 2
Completed	Lenalidomide in HTLV-1 Adult T-Cell Leukemia NCT01274533	Columbia University	Phase 2
Completed	A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients Wit NCT01169298	Celgene	Phase 1
Completed	Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 NCT01173887	Kyowa Kirin Co., Ltd.	Phase 2
Completed	A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy NCT01184885	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	EARLY_Phase 1
Completed	Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma NCT00920790	Kyowa Kirin Co., Ltd.	Phase 2